高强度聚焦超声消融治疗术后复发性硬纤维瘤的初步结果
研究纳入2017年9月至2020年5月42例病理证实的硬纤维瘤首次接受高强度聚焦超声消融的患者,分为术后复发组30例与非手术组12例。术后复发组肿瘤距皮肤最小距离6.9 mm显著小于非手术组10.8 mm(p=0.011),治疗平均声功率和强度显著低于非手术组(p=0.006和0.036),但消融疗效、中度不良事件发生率和平均住院时间组间无显著差异(p>0.05)。所有患者均成功完成消融并获得大体积凝固性坏死,无严重或危及生命的不良事件;手术瘢痕和肿瘤沿手术路径浸润对平均功率和强度有不利影响,但高强度聚焦超声消融仍可作为术后复发性硬纤维瘤局部控制的有效微创治疗。
要点
- 术后复发组肿瘤距皮肤最小距离6.9 mm,显著小于非手术组10.8 mm(p=0.011)。
- 术后复发组治疗平均声功率和强度显著低于非手术组(p=0.006和0.036)。
- 所有患者均成功消融并获得大体积凝固性坏死,无严重或危及生命的不良事件。
核心结论
- 高强度聚焦超声消融可成功用于术后复发性硬纤维瘤并获得大体积凝固性坏死,无严重或危及生命的不良事件;手术瘢痕和肿瘤沿手术路径浸润对平均功率和强度有不利影响,但该技术仍可作为术后复发性硬纤维瘤局部控制的有效微创治疗。
研究设计与样本
- 研究纳入2017年9月至2020年5月42例病理证实硬纤维瘤并首次接受高强度聚焦超声消融的连续患者,分为术后复发组30例与非手术组12例,记录并比较两组基本特征、治疗参数、消融疗效、耐受性和不良事件。
诊断标准与关键数值
- 术后复发组肿瘤距皮肤表面最小距离6.9 mm,非手术组10.8 mm,术后复发组显著更小(p=0.011)。
- 术后复发组治疗平均声功率和强度均显著低于非手术组(p=0.006和0.036)。
- 两组其余治疗参数及消融疗效无显著差异(p>0.05)。
- 两组中度不良事件发生率和平均住院时间无显著差异(p>0.05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
This study was aimed at evaluating the feasibility, safety and therapeutic effects of high-intensity focused ultrasound ablation (HIFUA) in the treatment of post-operative recurrent desmoid tumors. From September 2017 to May 2020, 42 consecutive patients with pathologically proven desmoid tumors treated with HIFUA for the first time were enrolled. These were divided into two groups: post-operative recurrent group (30 cases) and non-surgery group (12 cases). The basic characteristics, treatment parameters, ablation efficacy, tolerance and adverse events were recorded and compared between groups. The minimum distance between the tumor and skin surface in the post-operative recurrent group was significantly smaller than that in the non-surgery group (6.9 mm vs. 10.8 mm, p = 0.011), but there was no significant difference in the other basic characteristics (p > 0.05). The average acoustic power and intensity of treatment in the post-operative recurrent group were significantly lower than those in the non-surgery group (p = 0.006 and 0.036, respectively), but there was no significant difference in the remaining parameters or in ablation efficacy between groups (p > 0.05). HIFUA was successfully performed, and a large volume of coagulation necrosis was obtained from all patients without serious or life-threatening adverse events. Furthermore, there was no significant difference in the incidence of moderate adverse events and average length of stay between groups (p > 0.05). The average power and intensity of HIFUA treatment were adversely affected by surgical scar and tumor infiltration along the surgical path. However, HIFUA can still be used as an effective minimally invasive therapy for the local control of post-operative recurrent desmoid tumors.
引用
- Mo, Chen, Zhang, et al. High-Intensity Focused Ultrasound Ablation for Postoperative Recurrent Desmoid Tumors: Preliminary Results. Ultrasound Med Biol. 2022. PMID: 35039192. doi:10.1016/j.ultrasmedbio.2021.12.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。